Clinical Trial Update: ADI-PEG 20 in Combination With Gemcitabine and Docetaxel for the Treatment of Soft Tissue Sarcoma, Osteosarcoma, Ewing's Sarcoma, and Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial of ADI-PEG 20 in combination with gemcitabine and docetaxel for soft tissue sarcoma, osteosarcoma, Ewing's sarcoma, and small cell lung cancer has…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ewing Sarcoma
• Osteosarcoma
• Small Cell Lung Cancer
• Soft Tissue Sarcoma

Drugs mentioned

• ADI-PEG 20 (pegylated arginine deiminase)
• Gemzar (gemcitabine)
• Taxotere (docetaxel)

Snippet

Sponsor: Washington University School of Medicine | Conditions: Soft Tissue Sarcoma | Phase 2 | Status: COMPLETED | Results posted: 2023-09-08